P5_TA(2002)0561 Traditional herbal medicinal products ***I A5-0365/2002 European Parliament legislative resolution on the proposal for a European Parliament and Council directive amending Directive 2001/83/EC as regards traditional herbal medicinal products ( COM(2002) 1 – C5-0026/2002 – 2002/0008(COD)) (Codecision procedure: first reading) The European Parliament , – having regard to the Commission proposal to the European Parliament and the Council (COM(2002) 1 OJ C 126 E, 28.5.2002, p.263. ), – having regard to Article 251(2) and Article 95 of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament ( C5-0026/2002 ), – having regard to Rule 67 of its Rules of Procedure, – having regard to the report of the Committee on the Environment, Public Health and Consumer Policy ( A5-0365/2002 ), 1. Approves the Commission proposal as amended; 2. Asks to be consulted again should the Commission intend to amend the proposal substantially or replace it with another text; 3. Instructs its President to forward its position to the Council and Commission. P5_TC1-COD(2002)0008 Position of the European Parliament adopted at first reading on 21 November 2002 with a view to the adoption of European Parliament and Council Directive 2002/…/EC amending Directive 2001/83/EC as regards traditional herbal medicinal products THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof, Having regard to the proposal from the Commission OJ C 126 E, 28.5.2002, p. 263 . , Having regard to the opinion of the Economic and Social Committee OJ ... , Acting in accordance with the procedure laid down in Article 251 of the Treaty Position of the European Parliament of 21 November 2002 . , Whereas: (1) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use OJ L 311, 28.11.2001, p. 67. requires that applications for the authorisation to place a medicinal product on the market have to be accompanied by a dossier containing particulars and documents relating in particular to the results of physico-chemical, biological or microbiological as well as pharmacological and toxicological tests and clinical trials carried out on the product and thus proving its quality, safety and efficacy. (2) Where the applicant can demonstrate by detailed references to published scientific literature that the constituent or the constituents of the medicinal product have a